Page last updated: 2024-10-29

indomethacin and Bacterial Disease

indomethacin has been researched along with Bacterial Disease in 22 studies

Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.
indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.

Research Excerpts

ExcerptRelevanceReference
"The effect of indomethacin (1 mg/kg) on gas exchange was studied in ten patients with hypoxaemic respiratory failure precipitated by bacterial pneumonia."7.67Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. ( Dobson, K; Hanly, PJ; Light, RB; Roberts, D, 1987)
"The effect of indomethacin (1 mg/kg) on gas exchange was studied in ten patients with hypoxaemic respiratory failure precipitated by bacterial pneumonia."3.67Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia. ( Dobson, K; Hanly, PJ; Light, RB; Roberts, D, 1987)
"Pretreatment with indomethacin significantly decreased the proportion of fetal death from 83% to < 25% in mice injected with 10 micrograms of LPS."1.29Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide. ( Branch, DW; Dudley, DJ; Edwin, SS; Mitchell, MD; Silver, RM; Simmons, DL; Trautman, MS, 1995)
"Indomethacin sodium promotes closure of the patent ductus arteriosus in premature infants."1.27Indomethacin-associated sepsis in very-low-birth-weight infants. ( Eisenfeld, LI; Herson, VC; Krause, PJ; Maderazo, EG; Pontius, L, 1988)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-199012 (54.55)18.7374
1990's6 (27.27)18.2507
2000's2 (9.09)29.6817
2010's2 (9.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Shelke, SH1
Mhaske, PC1
Nandave, M1
Narkhade, S1
Walhekar, NM1
Bobade, VD1
McElroy, SJ1
Gordon, PV1
Attridge, JT1
Porras, M1
Martín, MT1
Soler, M1
Vergara, P1
Burke, V1
Gracey, M1
Korman, SH1
Berant, M1
Alon, U1
Horan, TD1
English, D1
McPherson, TA1
Friedman, CA1
Parks, BR1
Rawson, JE1
Serwer, GA1
Anderson, PA1
Meyer, TA1
Wang, J1
Tiao, GM1
Ogle, CK2
Fischer, JE3
Hasselgren, PO3
Silver, RM1
Edwin, SS1
Trautman, MS1
Simmons, DL1
Branch, DW1
Dudley, DJ1
Mitchell, MD1
Ohno, Y1
Kasugai, M1
Kurauchi, O1
Mizutani, S1
Tomoda, Y1
West, MA1
Manthei, R1
Bubrick, MP1
Newton, ER1
Shields, L1
Ridgway, LE1
Berkus, MD1
Elliott, BD1
Horgan, PG1
Mannick, JA1
Dubravec, DB1
Rodrick, ML1
Nakai, S1
Hirai, Y1
Kramarev, SA1
Hanly, PJ1
Roberts, D1
Dobson, K1
Light, RB1
Bihari, DJ1
Salzer, HR1
Salzer-Muhar, U1
Pollak, A1
Weninger, M1
Warner, BW2
Hummel, RP2
James, JH2
Herson, VC1
Krause, PJ1
Eisenfeld, LI1
Pontius, L1
Maderazo, EG1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)[NCT02409680]11,976 participants (Actual)Interventional2016-03-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Fetal Outcome 1 - Incidence of Early Preterm Delivery (<34 Weeks)

- Early preterm delivery (<34 weeks) (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm189
Placebo Arm230

Fetal Outcome 2 - Incidence of Actual Birth Weight <2500g

- Birth weight <2500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm1078
Placebo Arm1153

Fetal Outcome 3 - Incidence of Actual Birth Weight <1500g

- Birth weight <1500g (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm78
Placebo Arm101

Fetal Outcome 4 - Incidence of Fetal Loss

- Incidence of Fetal Loss (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm303
Placebo Arm353

Fetal Outcome 5 - Incidence of Spontaneous Abortion

- Incidence of Spontaneous Abortion (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm134
Placebo Arm152

Fetal Outcome 6 - Incidence of All Stillbirth

- Incidence of All stillbirth (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm141
Placebo Arm166

Fetal Outcome 7 - Incidence of Medical Termination of Pregnancy

- Incidence of Medical Termination of Pregnancy (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm42
Placebo Arm30

Incidence of Hypertensive Disorders of Pregnancy

- Hypertensive disorders of pregnancy is defined by the characterization of evidence of a hypertensive disorder, including either preeclampsia or eclampsia occurring during the pregnancy. (NCT02409680)
Timeframe: Evidence of hypertensive disorder during the pregnancy (prior to delivery/birth)

InterventionParticipants (Count of Participants)
Intervention Arm352
Placebo Arm325

Incidence of Perinatal Mortality

- Incidence of Perinatal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm264
Placebo Arm309

Incidence of Preterm Birth

The primary outcome of this study is incidence of preterm birth, which will be defined as delivery at or after 20 0/7 weeks and prior to 37 0/7 weeks. This will be determined based on actual date of delivery in comparison to the projected estimated due date (EDD), independent of whether or not the preterm delivery is indicated or spontaneous. (NCT02409680)
Timeframe: At delivery

InterventionParticipants (Count of Participants)
Intervention Arm668
Placebo Arm754

Incidence of Small for Gestational Age (SGA)

- Small for gestational age (SGA) as defined by the INTERGROWTH-21st standard (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm1506
Placebo Arm1564

Maternal Outcome 1 - Incidence of Vaginal Bleeding

- Vaginal bleeding (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm214
Placebo Arm246

Maternal Outcome 2 - Incidence of Antepartum Hemorrhage

- Antepartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm26
Placebo Arm25

Maternal Outcome 3 - Incidence of Postpartum Hemorrhage

- Postpartum hemorrhage (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm54
Placebo Arm43

Maternal Outcome 4 - Incidence of Maternal Mortality

- Incidence of Maternal Mortality (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm9
Placebo Arm12

Maternal Outcome 5 - Incidence of Late Abortion

- Incidence of Late Abortion (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm23
Placebo Arm30

Maternal Outcome 6 - Change in Maternal Hemoglobin

Hemoglobin < 7.0 gm/dl at 26-30 weeks gestation or a drop of 3.5+ gm/dl from screening to 26-30 weeks gestation (NCT02409680)
Timeframe: At enrollment, 4 weeks post enrollment, and 26-30 weeks GA.

InterventionParticipants (Count of Participants)
Intervention Arm290
Placebo Arm333

Maternal Outcome 7 - Incidence of Preterm, Preeclampsia

Early preterm delivery (<34 weeks) and hypertensive disorders (i.e.: preeclampsia) (NCT02409680)
Timeframe: At delivery or at Day 42 after delivery

InterventionParticipants (Count of Participants)
Intervention Arm8
Placebo Arm21

Reviews

2 reviews available for indomethacin and Bacterial Disease

ArticleYear
Understanding clinical literature relevant to spontaneous intestinal perforations.
    American journal of perinatology, 2009, Volume: 26, Issue:4

    Topics: Acute Disease; Bacterial Infections; Critical Care; Dexamethasone; Drug Therapy, Combination; Female

2009
Review: prostaglandins in diarrheal states.
    Israel journal of medical sciences, 1981, Volume: 17, Issue:12

    Topics: Aspirin; Bacterial Infections; Child; Cholera Toxin; Colonic Diseases; Cyclic AMP; Diarrhea; Dinopro

1981

Trials

1 trial available for indomethacin and Bacterial Disease

ArticleYear
Combination antibiotics and indomethacin in idiopathic preterm labor: a randomized double-blind clinical trial.
    American journal of obstetrics and gynecology, 1991, Volume: 165, Issue:6 Pt 1

    Topics: Ampicillin; Bacterial Infections; Double-Blind Method; Drug Therapy, Combination; Female; Humans; In

1991

Other Studies

19 other studies available for indomethacin and Bacterial Disease

ArticleYear
Synthesis and pharmacological evaluation of a novel series of 3-aryl-2-(2-substituted-4-methylthiazole-5-yl)thiazolidin-4-one as possible anti-inflammatory and antimicrobial agents.
    Bioorganic & medicinal chemistry letters, 2012, Oct-15, Volume: 22, Issue:20

    Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Bacteria; Bacterial Infections; Carrageena

2012
Unraveling the enigma that is neonatal necrotizing enterocolitis.
    Journal of perinatology : official journal of the California Perinatal Association, 2014, Volume: 34, Issue:10

    Topics: Bacterial Infections; Dexamethasone; Female; Humans; Indomethacin; Infant, Very Low Birth Weight; In

2014
Intestinal motor disorders associated with cyclical bacterial overgrowth in a rat model of enteritis.
    American journal of physiology. Gastrointestinal and liver physiology, 2004, Volume: 287, Issue:1

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Bacterial Infections; Bac

2004
Studies with enterotoxigenic microorganisms: effects of candidate antidiarrhoeals in experimental animals in vivo.
    Journal of pediatric gastroenterology and nutrition, 1984, Volume: 3, Issue:4

    Topics: Aluminum Hydroxide; Animals; Antidiarrheals; Aspirin; Bacterial Infections; Charcoal; Chlorpromazine

1984
Association of neutrophil chemiluminescence with microbicidal activity.
    Clinical immunology and immunopathology, 1982, Volume: 22, Issue:2

    Topics: 4-Chloromercuribenzenesulfonate; Ascorbic Acid; Bacterial Infections; Blood Bactericidal Activity; C

1982
Indomethacin and the preterm infant with a patent ductus arteriosus: relationship between plasma concentration and ductus closure.
    Developmental pharmacology and therapeutics, 1982, Volume: 4, Issue:1-2

    Topics: Bacterial Infections; Dose-Response Relationship, Drug; Ductus Arteriosus, Patent; Half-Life; Humans

1982
Sepsis and endotoxemia stimulate intestinal interleukin-6 production.
    Surgery, 1995, Volume: 118, Issue:2

    Topics: Animals; Bacterial Infections; Base Sequence; Dinoprostone; Endotoxins; Indomethacin; Interleukin-6;

1995
Bacterial lipopolysaccharide-mediated fetal death. Production of a newly recognized form of inducible cyclooxygenase (COX-2) in murine decidua in response to lipopolysaccharide.
    The Journal of clinical investigation, 1995, Volume: 95, Issue:2

    Topics: Abortion, Spontaneous; Animals; Bacterial Infections; Decidua; Dose-Response Relationship, Drug; Enz

1995
Effect of interleukin 2 on the production of progesterone and prostaglandin E2 in human fetal membranes and its consequences for preterm uterine contractions.
    European journal of endocrinology, 1994, Volume: 130, Issue:5

    Topics: Amniotic Fluid; Bacterial Infections; Chorioamnionitis; Culture Techniques; Dinoprostone; Extraembry

1994
Autoregulation of hepatic macrophage activation in sepsis.
    The Journal of trauma, 1993, Volume: 34, Issue:4

    Topics: Bacterial Infections; Cells, Cultured; Dinoprostone; Dose-Response Relationship, Drug; Homeostasis;

1993
Effect of low dose recombinant interleukin 2 plus indomethacin on mortality after sepsis in a murine burn model.
    The British journal of surgery, 1990, Volume: 77, Issue:4

    Topics: Animals; Bacterial Infections; Burns; Disease Models, Animal; Drug Therapy, Combination; Indomethaci

1990
The therapeutic potential of interleukin-1 beta in the treatment of chemotherapy- or radiation-induced myelosuppression and in tumor therapy.
    Biotherapy (Dordrecht, Netherlands), 1989, Volume: 1, Issue:4

    Topics: Animals; Antineoplastic Agents; Bacterial Infections; Bone Marrow; Combined Modality Therapy; Diseas

1989
[The use of indomethacin in acute intestinal infections].
    Vrachebnoe delo, 1989, Issue:4

    Topics: Acute Disease; Bacterial Infections; Child, Preschool; Convalescence; Dinoprost; Drug Evaluation; Hu

1989
Effect of indomethacin on arterial oxygenation in critically ill patients with severe bacterial pneumonia.
    Lancet (London, England), 1987, Feb-14, Volume: 1, Issue:8529

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Bacterial Infections; Critical Care; Humans; Hypoxia;

1987
Indomethacin and arterial oxygenation in critically ill patients with severe bacterial pneumonia.
    Lancet (London, England), 1987, Mar-28, Volume: 1, Issue:8535

    Topics: Arteries; Bacterial Infections; Critical Care; Humans; Indomethacin; Lung; Microcirculation; Oxygen;

1987
Sepsis and indomethacin failure in premature infants with symptomatic patent ductus arteriosus.
    Lancet (London, England), 1987, Apr-25, Volume: 1, Issue:8539

    Topics: Bacterial Infections; Ductus Arteriosus, Patent; Humans; Indomethacin; Infant, Newborn; Infant, Prem

1987
Further evidence that accelerated muscle protein breakdown during sepsis is not mediated by prostaglandin E2.
    Annals of surgery, 1988, Volume: 207, Issue:4

    Topics: Animals; Bacterial Infections; Dinoprostone; Indomethacin; Male; Muscle Proteins; Muscles; Prostagla

1988
Indomethacin-associated sepsis in very-low-birth-weight infants.
    American journal of diseases of children (1960), 1988, Volume: 142, Issue:5

    Topics: Bacterial Infections; Blood Bactericidal Activity; Cell Movement; Chemotaxis, Leukocyte; Ductus Arte

1988
Effects of indomethacin and leupeptin on muscle cathepsin B activity and protein degradation during sepsis.
    The Journal of surgical research, 1988, Volume: 45, Issue:1

    Topics: Animals; Bacterial Infections; Cathepsin B; Indomethacin; Leupeptins; Muscle Proteins; Muscles; Olig

1988